1. Home
  2. KOSS vs ANVS Comparison

KOSS vs ANVS Comparison

Compare KOSS & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Koss Corporation

KOSS

Koss Corporation

HOLD

Current Price

$3.91

Market Cap

39.3M

ML Signal

HOLD

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$1.96

Market Cap

69.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOSS
ANVS
Founded
1953
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.3M
69.1M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
KOSS
ANVS
Price
$3.91
$1.96
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
17.7K
979.1K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
10.00
39.39
EPS
N/A
N/A
Revenue
$12,624,170.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.93
N/A
52 Week Low
$3.50
$1.54
52 Week High
$8.59
$5.50

Technical Indicators

Market Signals
Indicator
KOSS
ANVS
Relative Strength Index (RSI) 48.81 55.14
Support Level $3.79 $1.92
Resistance Level $4.19 $2.07
Average True Range (ATR) 0.16 0.10
MACD 0.00 0.03
Stochastic Oscillator 48.59 76.00

Price Performance

Historical Comparison
KOSS
ANVS

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.

About ANVS Annovis Bio Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Share on Social Networks: